Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography

BACKGROUND: Few studies that have assessed the effect of abbrcviated oral Nacctylcysteine (NAC) rcgimens in radiocontrast-induced nephropat hy (RCIN)yield mixed results. OBJECTJVE: To evaluate the rcnoprotective effect of high periprocedural oral doses (HPOD) of NAC in patients with chronic renal im...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Baderramo, Domingo, Badra Verdu, Mariano, Ramacciotti , Constanza, Cremona, Luis, Lemos, Pablo, Orías, Marcelo, Moreyra Jr, Eduardo
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2004
Materias:
N-acetylcysteine
contrast media
angiography
acute renal failure
N- acetilcisteina
Medio de contraste
Angiografía
Insuficiencia renal aguda
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/33031
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
id I10-R327-article-33031
record_format ojs
spelling I10-R327-article-330312021-06-29T15:31:50Z Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography Efecto renoprotector de altas dosis periprocedimiento de n-acetilcisteína oral en pacientes programados para someterse a una angiografía el mismo día Baderramo, Domingo Badra Verdu, Mariano Ramacciotti , Constanza Cremona, Luis Lemos, Pablo Orías, Marcelo Moreyra Jr, Eduardo N-acetylcysteine contrast media angiography acute renal failure N- acetilcisteina Medio de contraste Angiografía Insuficiencia renal aguda BACKGROUND: Few studies that have assessed the effect of abbrcviated oral Nacctylcysteine (NAC) rcgimens in radiocontrast-induced nephropat hy (RCIN)yield mixed results. OBJECTJVE: To evaluate the rcnoprotective effect of high periprocedural oral doses (HPOD) of NAC in patients with chronic renal impairmcnt undergoing a same-day angiography. METHODS: Sixty one paticnts vi1Ii renal impaired function scheduled to undcrgo a same-day angiography were randomly assigned to NAC 1200 ing orally 3 hours before and 3 after the procedure, or a placebo. Al! patients received 0.9% salme intravenous. RCIN was defined as an increase in SCC > 0.5 mg/dl 48 hours after the procedure. RESULTS: The mean baseline SCC for all patients was 1.44 ± 0.42 mg/dl. A slgnificant difference in SCC change at 48 hours after the angiography was found (-0.07 mg/dl NAC, 0.09 mg/dl placebo, P=0.04). RCIN occurred in 1 (3%)patient of NAC group and in 2 (7.1%) patients of placebo group (P=0.59). Adverse effects were similar in both groups. CONCLUSIONS: In patients withmild renal impairment patients undergoing angiographic procedures. HPOD of NAC were more effective than placebo in preventing SCC change 48 hours. A non slgnlficant benefit in RCIN incidence vas found. ANTECEDENTES: Los escasos estudios i tic han evaluados los efectos de regimenes abreviados tic Nacctiicisteína (NAC) oral en la nefropatía por contraste (NC) han encontrarl resultados contrapuestos. OBJETIVO: Evaluar el efecto renoprotector de altas dosis orales periproceclimiento (ADOP) ele NAC en pacientes con insuficiencia renal con angiografía programada el mismo cija. MATERIAL Y METODOS: Sesenta y un pacientes con insuficiencia renal y angiografía programada para el mismo día fueron asignados aleatoriamente a 1200 mg de NAC 3 horas previas y 3 horas posteriores al cateterismo o un placebo. Todos los pacientes recibieron hidratación endovenosa con solución salina al 0.9%. La NC se definió como el aumento en la creatinina sérica (CS) > 0.5 mg/dl a las 48 horas del procedimiento. RESULTADOS: La CS media en todos los pacientes fue 1,44 ± 0.42 mg/dl. Se encontró una diferencia significativa entre ambos grupos en el cambio de CS a las 48 horas tic la angiografía (-0.07 mg/d1 NAC, 0.09 mg/dl placebo, P=0.04). La NC se presentó en 1 (3%) paciente del grupo NAC y en 2(7.1%) pacientes del grupo placebo (P=0.59). Los efectos adversos fueron similares en ambos grupos. CONCLUSION: Enpacientes con insuficiencia renal leve sometidos a angiografía en el mismo tija, las ADOP de NAC fueron más efectivas que el placebo cii la prevención del cambio tic CS a las 48 horas del procedimiento. Se encontró un beneficio no significativo en la incidencia de NC Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2004-06-09 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/33031 10.31053/1853.0605.v61.n2.33031 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 61 No. 2 (2004); 15 -19 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 61 Núm. 2 (2004); 15 -19 Revista da Faculdade de Ciências Médicas de Córdoba; v. 61 n. 2 (2004); 15 -19 1853-0605 0014-6722 spa https://revistas.unc.edu.ar/index.php/med/article/view/33031/33569 Derechos de autor 2021 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-327
container_title_str Revista de la Facultad de Ciencias Médicas de Córdoba
language Español
format Artículo revista
topic N-acetylcysteine
contrast media
angiography
acute renal failure
N- acetilcisteina
Medio de contraste
Angiografía
Insuficiencia renal aguda
spellingShingle N-acetylcysteine
contrast media
angiography
acute renal failure
N- acetilcisteina
Medio de contraste
Angiografía
Insuficiencia renal aguda
Baderramo, Domingo
Badra Verdu, Mariano
Ramacciotti , Constanza
Cremona, Luis
Lemos, Pablo
Orías, Marcelo
Moreyra Jr, Eduardo
Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography
topic_facet N-acetylcysteine
contrast media
angiography
acute renal failure
N- acetilcisteina
Medio de contraste
Angiografía
Insuficiencia renal aguda
author Baderramo, Domingo
Badra Verdu, Mariano
Ramacciotti , Constanza
Cremona, Luis
Lemos, Pablo
Orías, Marcelo
Moreyra Jr, Eduardo
author_facet Baderramo, Domingo
Badra Verdu, Mariano
Ramacciotti , Constanza
Cremona, Luis
Lemos, Pablo
Orías, Marcelo
Moreyra Jr, Eduardo
author_sort Baderramo, Domingo
title Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography
title_short Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography
title_full Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography
title_fullStr Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography
title_full_unstemmed Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography
title_sort renoproctective effect of hight periprocedural doses of oral n- acetylcysteine in patients scheduled to undergo a same - day angiography
description BACKGROUND: Few studies that have assessed the effect of abbrcviated oral Nacctylcysteine (NAC) rcgimens in radiocontrast-induced nephropat hy (RCIN)yield mixed results. OBJECTJVE: To evaluate the rcnoprotective effect of high periprocedural oral doses (HPOD) of NAC in patients with chronic renal impairmcnt undergoing a same-day angiography. METHODS: Sixty one paticnts vi1Ii renal impaired function scheduled to undcrgo a same-day angiography were randomly assigned to NAC 1200 ing orally 3 hours before and 3 after the procedure, or a placebo. Al! patients received 0.9% salme intravenous. RCIN was defined as an increase in SCC > 0.5 mg/dl 48 hours after the procedure. RESULTS: The mean baseline SCC for all patients was 1.44 ± 0.42 mg/dl. A slgnificant difference in SCC change at 48 hours after the angiography was found (-0.07 mg/dl NAC, 0.09 mg/dl placebo, P=0.04). RCIN occurred in 1 (3%)patient of NAC group and in 2 (7.1%) patients of placebo group (P=0.59). Adverse effects were similar in both groups. CONCLUSIONS: In patients withmild renal impairment patients undergoing angiographic procedures. HPOD of NAC were more effective than placebo in preventing SCC change 48 hours. A non slgnlficant benefit in RCIN incidence vas found.
publisher Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2004
url https://revistas.unc.edu.ar/index.php/med/article/view/33031
work_keys_str_mv AT baderramodomingo renoproctectiveeffectofhightperiproceduraldosesoforalnacetylcysteineinpatientsscheduledtoundergoasamedayangiography
AT badraverdumariano renoproctectiveeffectofhightperiproceduraldosesoforalnacetylcysteineinpatientsscheduledtoundergoasamedayangiography
AT ramacciotticonstanza renoproctectiveeffectofhightperiproceduraldosesoforalnacetylcysteineinpatientsscheduledtoundergoasamedayangiography
AT cremonaluis renoproctectiveeffectofhightperiproceduraldosesoforalnacetylcysteineinpatientsscheduledtoundergoasamedayangiography
AT lemospablo renoproctectiveeffectofhightperiproceduraldosesoforalnacetylcysteineinpatientsscheduledtoundergoasamedayangiography
AT oriasmarcelo renoproctectiveeffectofhightperiproceduraldosesoforalnacetylcysteineinpatientsscheduledtoundergoasamedayangiography
AT moreyrajreduardo renoproctectiveeffectofhightperiproceduraldosesoforalnacetylcysteineinpatientsscheduledtoundergoasamedayangiography
AT baderramodomingo efectorenoprotectordealtasdosisperiprocedimientodenacetilcisteinaoralenpacientesprogramadosparasometerseaunaangiografiaelmismodia
AT badraverdumariano efectorenoprotectordealtasdosisperiprocedimientodenacetilcisteinaoralenpacientesprogramadosparasometerseaunaangiografiaelmismodia
AT ramacciotticonstanza efectorenoprotectordealtasdosisperiprocedimientodenacetilcisteinaoralenpacientesprogramadosparasometerseaunaangiografiaelmismodia
AT cremonaluis efectorenoprotectordealtasdosisperiprocedimientodenacetilcisteinaoralenpacientesprogramadosparasometerseaunaangiografiaelmismodia
AT lemospablo efectorenoprotectordealtasdosisperiprocedimientodenacetilcisteinaoralenpacientesprogramadosparasometerseaunaangiografiaelmismodia
AT oriasmarcelo efectorenoprotectordealtasdosisperiprocedimientodenacetilcisteinaoralenpacientesprogramadosparasometerseaunaangiografiaelmismodia
AT moreyrajreduardo efectorenoprotectordealtasdosisperiprocedimientodenacetilcisteinaoralenpacientesprogramadosparasometerseaunaangiografiaelmismodia
first_indexed 2024-09-03T21:02:29Z
last_indexed 2024-09-03T21:02:29Z
_version_ 1809210251677794304

Ejemplares similares